Pharmacology




© Springer International Publishing Switzerland 2017
Hardik P. Amin and Joseph L. Schindler (eds.)Vascular Neurology Board Review10.1007/978-3-319-39605-7_19


19. Pharmacology



Hardik P. Amin  and Joseph L. Schindler 


(1)
Assistant Professor of Neurology, Yale University School of Medicine, Associate Director, Vascular Neurology Fellowship, Yale-New Haven Hospital, New Haven, Connecticut, USA

(2)
Associate Professor of Neurology and Neurosurgery, Yale University School of Medicine, Director, Acute Stroke and TeleStroke Services, Director, Vascular Neurology Fellowship, Yale-New Haven Hospital, New Haven, Connecticut, USA

 



 

Hardik P. Amin (Corresponding author)



 

Joseph L. Schindler



Abbreviations


ACE-I

Angiotensin-converting enzyme inhibitor

ADP

Adenosine diphosphate

AF

Atrial fibrillation

ARB

Angiotensin II receptor blocker

ASA

Acetylsalicylic acid

AV

Atrioventricular

BB

Beta-blocker

CAMP

Cyclic adenosine monophosphate

CCB

Calcium channel blocker

CHF

Congestive heart failure

CK

Creatine kinase

COX

Cyclooxygenase

DM

Diabetes mellitus

GI

Gastrointestinal

HCTZ

Hydrochlorothiazide

HDL

High-density lipoprotein

HMGCoA

3-Hydroxy-3-methylglutaryl-coenzyme A

HTN

Hypertension

ICP

Intracranial pressure

INR

International normal ratio

LDL

Low-density lipoprotein

LFT

Liver function enzymes

LMWH

Low molecular weight heparin

PPI

Proton pump inhibitor

TG

Triglycerides

TPA

Tissue plasminogen activator



Introduction


The management of patients with cerebrovascular disease has become complex given the severity of concomitant medical comorbidities. An understanding of the clinical indication and pharmacological basis for stroke therapeutics is critical. Many of these treatments are initiated by neurologists shortly after an acute stroke for prompt secondary prevention. Additionally, many vascular neurologists will oversee therapeutics used to treat thrombosis, hypertension , and hyperlipidemia in the outpatient setting along with cardiologists and internists.


Antihypertensives






  • Diuretics: act on kidneys to increase Na excretion



    • Standard first-line therapy for essential HTN


    • Thiazides: best used in mild to moderate HTN



      • HCTZ (watch for hypokalemia)


    • Loop diuretics: severe HTN



      • Furosemide


    • K-sparing: spironolactone, triamterene, amiloride


    • SE: hypokalemia, hyperlipidemia, hyper best used in glycemia


  • Beta-blockers (BB)



    • Reduce cardiac output, inhibit renin release, may decrease adrenergic outflow, and mask symptoms of hypoglycemia


    • More effective in whites than African Americans, and in younger patients than older


    • Nonselective



      • Labetalol: combined alpha- and beta-blockade, β1 + β2 > α1 receptor antagonist


      • Propranolol


    • Cardioselective (β1 receptor antagonists)



      • Metoprolol


      • Atenolol


      • Esmolol: rapid acting, short duration


    • Adverse effects



      • Abrupt withdrawal: tachycardia, nervousness, hypertension


      • Use with caution in asthmatics, recent cocaine use (due to postulated un-opposed α effect, exacerbating coronary vasospasm)


      • May increase triglycerides, decrease HDL


  • Alpha blockers

Oct 7, 2017 | Posted by in NEUROLOGY | Comments Off on Pharmacology

Full access? Get Clinical Tree

Get Clinical Tree app for offline access